Miguel Vega, M.Eng & PDD-IESE
CEO at Allinky Biopharma.
From 2003 to 2011, Miguel served as the Director of Studies & Innovation, and Head of Technology Transfer, at the Spanish National Foundation for Genomics and Biotechnology (Genoma España). During this period he participated actively and co-led of one of the largest Public Biotechnology Seed Capital Funds in Spain. Before 2003, Miguel held different positions as: Director for Entrepreneurship and Business Development at the Madrid Science Park; Head of the Biotechnology Innovation Program at the Madrid Regional Platform for Science and Technology; and Scientific Agent at the Institute for Prospective Technological Studies (IPTS) of the European Commission. Miguel holds a Degree in Bioprocess Engineering from the Universidad Politécnica de Madrid and a Diploma from the Program for General Management (PDD) run by the IESE Business School.
Esther Carrasco, Ph.D.
Head of Medicinal Chemistry-Inflammation, Allinky Biopharma
Esther Carrasco is an active and skilled chemist with almost a decade of experience in chemical synthesis for lead optimization. In 2011, Esther joined Allinky to lead different medicinal chemistry projects to optimize lead compounds or molecules targeting novel routes in inflammation and cancer. Esther received her PhD degree ‘cum laude’ in organic chemistry from the University of Extremadura (Spain). Prior to entering Allinky, Esther was a member of the Institute of Advanced Chemistry of Catalonia, which pertains to the Spanish Higher National Research Council (CSIC) under the coordination of Professor Angel Messeguer.
Pedro Campos, Ph.D.
Head of Molecular and Cell Biology, Allinky Biopharma.
Pedro has more than eight years of research experience focusing on the discovery and development of allosteric modulators of MAP Kinases. He has been actively involved in the use and development of novel technological platforms for the identification and validation of allosteric compound. Pedro is a Chemical Biologist by training who studied at the Universidad Autónoma de Madrid and who received his PhD degree from the “Severo Ochoa” Centre for Molecular Biology of the Spanish Higher National Research Council (CBM-CSIC).
Patricia Gómez, Ph.D.
Head of Computational Chemistry, Allinky Biopharma.
Patricia has more than seven years of research experience in the discovery and development of allosteric modulators of GPCR and MAP Kinases. She has been actively involved in the in silico design of allosteric compounds that are currently undergoing regulatory preclinical and clinical studies. Patricia is a Chemist by training who graduated from the University of Barcelona (Spain) and who obtained her PhD degree from the Polytechnic University of Catalonia.
Asunción Burguete, Ph.D.
Head of Medicinal Chemistry-Oncology, Allinky Biopharma
Asunción is a chemist by training with more than five years experience in chemical synthesis. In 2011, Asunción joined Allinky to participate in different medicinal chemistry projects to optimize lead molecules that target novel routes in inflammation and cancer. Asunción received her PhD degree 'cum laude' in organic chemistry from the University of Navarra (Spain). Prior to joining Allinky, Asunción was a member of Professor Angel Messeguer's research group at the Institute of Advanced Chemistry of Catalonia, which belongs to the Spanish Higher National Research Council (CSIC).